C130050O18Rik Inhibitors
C130050O18Rik is a gene product whose precise function remains elusive. However, emerging evidence suggests its involvement in intricate cellular signaling pathways. It may play roles in regulating the EGFR, TGF-β, B-cell, PI3K-AKT, JNK, and NF-κB pathways, positioning itself as a key orchestrator in cellular signaling dynamics. The protein's participation in these pathways implies potential roles in cell proliferation, differentiation, survival, and gene expression modulation.
The inhibitors listed above target specific pathways associated with C130050O18Rik, providing potential avenues for modulation. Lapatinib and Trametinib, for instance, disrupt the EGFR and MAPK pathways, respectively, indirectly influencing C130050O18Rik and potentially regulating cellular proliferation. SB431542, a TGF-β receptor inhibitor, may impact cellular differentiation processes associated with C130050O18Rik. GDC-0941 and Wortmannin, as PI3K inhibitors, can contribute to alterations in cell survival mechanisms linked to C130050O18Rik. These inhibitors collectively offer valuable insights into the potential regulatory mechanisms of C130050O18Rik in cellular signaling pathways, opening avenues for further exploration in cellular biology research.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib, a dual EGFR/HER2 inhibitor, disrupts the EGFR pathway. Its inhibition of EGFR may indirectly modulate C130050O18Rik, affecting cellular signaling associated with proliferation. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 inhibits TGF-β receptors, disrupting the TGF-β signaling pathway. Its interference in this cascade may indirectly impact C130050O18Rik, potentially regulating cell differentiation. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Ibrutinib, a BTK inhibitor, disrupts B-cell signaling. Its influence on B-cell pathways can indirectly affect C130050O18Rik, potentially regulating cellular responses and gene expression. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
GDC-0941 is a PI3K inhibitor, affecting the PI3K-AKT pathway. Its interference in this cascade may indirectly impact C130050O18Rik, contributing to alterations in cell survival mechanisms. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 targets mTOR, impacting the mTOR signaling pathway. Its modulation of mTOR pathways may indirectly influence C130050O18Rik, potentially altering cellular responses and gene expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, disrupts JNK signaling. Its influence on JNK pathways can indirectly affect C130050O18Rik, potentially regulating cellular responses and gene expression. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a multi-kinase inhibitor, targets BCR-ABL and Src family kinases. Its interference in these pathways may indirectly impact C130050O18Rik, affecting cellular signaling dynamics. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor, disrupting the MAPK pathway. By modulating this pathway, it indirectly influences C130050O18Rik, suggesting a regulatory role in cellular proliferation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits PI3K, affecting the PI3K-AKT pathway. Its interference in this cascade may indirectly impact C130050O18Rik, contributing to alterations in cell survival mechanisms. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
(+/-)-JQ1 is a BET bromodomain inhibitor, disrupting BET proteins. Its influence on BET proteins can indirectly affect C130050O18Rik, potentially modulating cellular responses and gene expression. | ||||||